These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 15570081

  • 1. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
    Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S, Reddick WE.
    J Clin Oncol; 2004 Dec 01; 22(23):4795-803. PubMed ID: 15570081
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov 01; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan 01; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 4. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network.
    Arch Gen Psychiatry; 2005 Nov 01; 62(11):1266-74. PubMed ID: 16275814
    [Abstract] [Full Text] [Related]

  • 5. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J, Pliszka SR.
    J Pediatr; 2008 Mar 01; 152(3):394-9. PubMed ID: 18280848
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 7. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

  • 8. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 15; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 9. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ.
    Pediatrics; 1996 Oct 15; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S.
    J Clin Pharm Ther; 2004 Apr 15; 29(2):139-44. PubMed ID: 15068402
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar 15; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 12. Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors.
    Helton SC, Corwyn RF, Bonner MJ, Brown RT, Mulhern RK.
    J Pediatr Psychol; 2006 Mar 15; 31(2):200-8. PubMed ID: 16467320
    [Abstract] [Full Text] [Related]

  • 13. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.
    Pearson DA, Lane DM, Santos CW, Casat CD, Jerger SW, Loveland KA, Faria LP, Mansour R, Henderson JA, Payne CD, Roache JD, Lachar D, Cleveland LA.
    J Am Acad Child Adolesc Psychiatry; 2004 Jun 15; 43(6):686-98. PubMed ID: 15167085
    [Abstract] [Full Text] [Related]

  • 14. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
    Coghill DR, Rhodes SM, Matthews K.
    Biol Psychiatry; 2007 Nov 01; 62(9):954-62. PubMed ID: 17543895
    [Abstract] [Full Text] [Related]

  • 15. The effect of methylphenidate on the cognitive and personality functioning of ADHD children.
    Lufi D, Parish-Plass J, Gai E.
    Isr J Psychiatry Relat Sci; 1997 Nov 01; 34(3):200-9. PubMed ID: 9334525
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ.
    BMC Psychiatry; 2004 Sep 30; 4():28. PubMed ID: 15458569
    [Abstract] [Full Text] [Related]

  • 17. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial.
    Conklin HM, Khan RB, Reddick WE, Helton S, Brown R, Howard SC, Bonner M, Christensen R, Wu S, Xiong X, Mulhern RK.
    J Pediatr Psychol; 2007 Oct 30; 32(9):1127-39. PubMed ID: 17569711
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 30; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 19. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer.
    Thompson SJ, Leigh L, Christensen R, Xiong X, Kun LE, Heideman RL, Reddick WE, Gajjar A, Merchant T, Pui CH, Hudson MM, Mulhern RK.
    J Clin Oncol; 2001 Mar 15; 19(6):1802-8. PubMed ID: 11251012
    [Abstract] [Full Text] [Related]

  • 20. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.